Lymphoma, Extranodal NK-T-Cell
16
2
2
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
18.8%
3 terminated out of 16 trials
40.0%
-46.5% vs benchmark
6%
1 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (16)
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
AEDV Registry of Primary Cutaneous Lymphoma
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
MESA Treatment for NK/T Cell Lymphoma